Obesity and uncontrolled risk factors dominate cardiometabolic multimorbidity in Ghanaian clinics
In a Ghanaian tertiary-care cohort, cardiometabolic multimorbidity emerged as the rule rather than the exception. More than 80% of the 203 adults attending specialized clinics in Cape Coast carried at least two cardiometabolic conditions, and more than 80% were overweight or obese. Two-thirds or more met criteria for metabolic syndrome, creating a clinical picture in which hypertension, dysglycemia, excess adiposity and kidney disease were overlapping instead of isolated problems.
The pattern matters because these disorders reinforce one another through shared biology. Insulin resistance, sodium retention, vascular dysfunction, inflammation and progressive renal injury do not move independently; they cluster, amplify one another and raise the probability of cardiovascular events, disability and premature death. In settings where clinic access often comes late in the disease course, that clustering can leave little margin for rescue once organ damage has accumulated.
A cross-sectional clinic cohort with integrated clinical and genetic testing
The study enrolled adults between 17 May 2023 and 30 April 2024 at a tertiary hospital in Cape Coast, Ghana. Investigators collected sociodemographic and clinicodemographic data, alongside lifestyle information gathered through structured questionnaires. They then layered on genotyping for a focused panel of candidate variants: TCF7L2 rs7903146, AGT rs699, ACE rs4343, LEPR rs1137101, ADRB3 rs4994, KCNJ11 rs5219, PPARG rs1801282 and APOL1 risk variants.
That design is clinically useful because it tests a familiar question in a real-world African clinic population: how much of the burden is explained by modifiable factors, and how much signal remains once common genetic markers are added to the model? The answer here leans heavily toward modifiable risk. Clinical and lifestyle data carried much of the predictive weight, while the genetic-only models lagged behind.
Blood pressure and glucose control were better with treatment, but still imperfect
Treatment exposure tracked with better control, yet the cohort still showed substantial residual disease. Use of glucose-lowering medication was associated with better glycemic control, with an odds ratio of 7.16 and a 95% confidence interval of 3.31 to 15.47. Antihypertensive treatment was associated with lower odds of uncontrolled blood pressure, with an adjusted odds ratio of 0.25 and a 95% confidence interval of 0.07 to 0.90.
Those findings are straightforward but clinically important. They show that pharmacotherapy was doing something measurable in this population, even if many patients remained above target. In high-burden cardiometabolic care, treatment does not erase risk immediately; it narrows it. Persistent uncontrolled blood pressure and hyperglycemia still leave the arterial tree, kidneys and myocardium exposed to ongoing injury.
Obesity carried the sharpest association with kidney disease. Obese I and Obese II categories were the strongest independent predictors of CKD, with adjusted odds ratios in the range of 7 to 8. The signal fits established pathophysiology: excess adiposity increases glomerular hyperfiltration, raises blood pressure load, worsens insulin resistance and accelerates albuminuric injury. Over time, the kidney becomes a downstream casualty of metabolic stress.
Genetic signals were limited, with one TCF7L2 association standing out
Among the candidate variants, only one result reached clear statistical separation from the rest of the panel. The TCF7L2 rs7903146 CT genotype was associated with higher odds of hypertension, with an adjusted odds ratio of 2.15 and a 95% confidence interval of 1.06 to 4.37. Most of the other variants, including APOL1, did not show consistent associations in this cohort.
This is not a reason to overread the genetics. The study was explicitly exploratory, and the negative findings are just as informative as the single positive signal. In a cohort dominated by obesity, blood pressure elevation and glucose dysregulation, candidate variants may have relatively small effects or effects that are difficult to detect without larger sample sizes and community-based sampling. The genetic architecture of cardiometabolic disease is likely present, but it was not the main driver of the clinical burden measured here.
Combined models outperformed genetic data alone
Predictive performance favored integrated models. Combined clinical, lifestyle and genetic models produced the highest discrimination, with area under the curve values from 0.83 to 0.89. Clinical and lifestyle models alone still performed well, with AUCs from 0.76 to 0.83. Genetic-only models performed poorly, with AUCs from 0.63 to 0.67.
The gradient is clinically intuitive. Bedside variables such as body weight, treatment use, blood pressure and glycemic status remain more immediately informative than a limited set of candidate variants. Genes may help refine risk, but they did not replace conventional clinical assessment here. For everyday practice, the practical message is that the strongest near-term gains are likely to come from identifying obesity early, improving treatment coverage and tightening control of blood pressure and glucose.
What this means for integrated care in Ghana
This study places a heavy burden of cardiometabolic disease in sharp relief. The cohort was not defined by a single disorder; it was defined by overlap, persistence and incomplete control. In that setting, fragmentation of care becomes a liability. Hypertension clinics, diabetes care, weight management and kidney surveillance need to function as linked services rather than separate silos.
The findings also argue for a preventive approach that does not wait for late CKD or entrenched multimorbidity. Obesity appears to be the clearest modifiable pivot point in this dataset. If excess weight is driving both metabolic syndrome and kidney risk, then diet, physical activity, medication adherence and earlier clinical intervention become more than general advice; they become the most direct route to lowering the combined cardiometabolic load.
The authors frame the genetic findings as exploratory, and that caution should be preserved. The cohort was modest in size and drawn from specialized clinics, which limits how widely the results can be generalized. A larger, community-based study would be needed to determine whether the same clinical patterns hold outside tertiary care and whether the observed genetic associations persist in broader Ghanaian populations.
For now, the signal is clear enough for clinicians to act on the factors already visible at the bedside: obesity, blood pressure, glycemia and kidney function. In this cohort, those variables carried more immediate predictive value than any single genetic marker, and they remain the most actionable targets for integrated cardiometabolic care.
Reference: Gavor-Kwashi CEK, Ryabinina O, Badu Nyarko S, Aku Addo N, Twum JA, Anyimadu J, et al. Cardiometabolic multimorbidity and associated clinical, lifestyle and genetic factors among Ghanaian patients. PLoS One. 2026;21(11):e0362848. DOI: 10.1371/journal.pone.0362848
- • PLOS One article DOI 10.1371/journal.pone.0362848: https://doi.org/10.1371/journal.pone.0362848